Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2021-03-30 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
毕马威华振会计师事务所（特殊普通合伙）关于前沿生物药业（南京）股份有限公司2020年度审计报告
Regulatory Filings
2021-03-30 Chinese
前沿生物关于艾可宁获得厄瓜多尔药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a drug registration certificate in Ecuador. It details the product, its significance, market impact, and risk factors. The document is short (1225 characters) and does not contain financial statements or detailed financial data. It is an announcement of a regulatory approval event rather than a financial report or management discussion. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement about a product approval and market expansion. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-03-17 Chinese
前沿生物2021年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2021 first extraordinary general meeting of shareholders of the company. It includes information about the meeting date, location, attendance, voting results on various proposals, and legal witness statements. The content focuses on the voting outcomes and procedural details of the shareholders' meeting rather than presenting a full annual or interim report, financial statements, or management discussion. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and contains detailed voting results, not just a brief announcement or a link to a report, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is DVA with high confidence.
2021-02-25 Chinese
前沿生物关于2021年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider information and stock trading activities related to the company's 2021 restricted stock incentive plan. It details the investigation scope, procedures, and conclusions about insider trading compliance. It is not a financial report, earnings release, or management discussion. It is a regulatory announcement about compliance and insider trading self-check, which fits best under Regulatory Filings (RNS). The document length is short and it is an announcement rather than a full report or financial statement.
2021-02-25 Chinese
前沿生物2020年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled '2020 年度业绩快报公告' which translates to '2020 Annual Performance Express Report Announcement'. It contains preliminary financial data for the year 2020, including revenue, profit, assets, and equity figures. The data is explicitly stated as preliminary and unaudited, with a note that the final audited data will be disclosed in the company's 2020 Annual Report. The document is relatively short (1841 characters) and serves as a quick financial performance update rather than a full annual report. It does not contain comprehensive financial statements or detailed analysis, but rather a summary of key financial metrics and a risk warning. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the appropriate classification is ER with high confidence. FY 2020
2021-02-25 Chinese
国浩律师（南京）事务所关于前沿生物药业（南京）股份有限公司2021年第一次临时股东大会的法律意见书
Regulatory Filings
2021-02-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.